HUS1300027I1 - Aktív összetevõként ecetsav-anilid származékait tartalmazó orvosság túlmûködõ húgyhólyag kezelésére - Google Patents

Aktív összetevõként ecetsav-anilid származékait tartalmazó orvosság túlmûködõ húgyhólyag kezelésére

Info

Publication number
HUS1300027I1
HUS1300027I1 HUS1300027C HUS1300027C HUS1300027I1 HU S1300027 I1 HUS1300027 I1 HU S1300027I1 HU S1300027 C HUS1300027 C HU S1300027C HU S1300027 C HUS1300027 C HU S1300027C HU S1300027 I1 HUS1300027 I1 HU S1300027I1
Authority
HU
Hungary
Prior art keywords
bladder
remedy
acid anilide
acetic acid
active ingredient
Prior art date
Application number
HUS1300027C
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1300027(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of HUS1300027I1 publication Critical patent/HUS1300027I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUS1300027C 2002-11-07 2013-06-19 Aktív összetevõként ecetsav-anilid származékait tartalmazó orvosság túlmûködõ húgyhólyag kezelésére HUS1300027I1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja) 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
EP03770134A EP1559427B1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Publications (1)

Publication Number Publication Date
HUS1300027I1 true HUS1300027I1 (hu) 2016-08-29

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
HUS1300027C HUS1300027I1 (hu) 2002-11-07 2013-06-19 Aktív összetevõként ecetsav-anilid származékait tartalmazó orvosság túlmûködõ húgyhólyag kezelésére

Country Status (28)

Country Link
US (5) USRE44872E1 (enExample)
EP (1) EP1559427B1 (enExample)
JP (1) JP3815496B2 (enExample)
KR (1) KR100967070B1 (enExample)
CN (1) CN100406011C (enExample)
AT (1) ATE500827T1 (enExample)
AU (1) AU2003284700B2 (enExample)
BE (1) BE2013C040I2 (enExample)
BR (1) BR0316080A (enExample)
CA (1) CA2503570C (enExample)
CY (2) CY1111399T1 (enExample)
DE (1) DE60336334D1 (enExample)
DK (1) DK1559427T3 (enExample)
ES (1) ES2360353T3 (enExample)
FR (1) FR13C0032I2 (enExample)
HU (1) HUS1300027I1 (enExample)
IL (1) IL168121A (enExample)
LU (1) LU92218I2 (enExample)
MX (1) MXPA05004925A (enExample)
NL (1) NL300599I2 (enExample)
NO (2) NO334948B1 (enExample)
NZ (1) NZ539577A (enExample)
PL (1) PL211687B1 (enExample)
PT (1) PT1559427E (enExample)
RU (1) RU2321401C2 (enExample)
SI (1) SI1559427T1 (enExample)
WO (1) WO2004041276A1 (enExample)
ZA (1) ZA200503510B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
WO2009081837A1 (ja) 2007-12-21 2009-07-02 Astellas Pharma Inc. 下部尿路症状の改善用医薬組成物
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5553767B2 (ja) * 2008-11-07 2014-07-16 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
US8586760B2 (en) * 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
EP2709993A4 (en) 2011-05-18 2015-02-25 Reddys Lab Ltd Dr AMORPHIC MIRABEGRON AND METHOD FOR CRYSTALLINE FORMS OF MIRABEGRON
EP2832730A4 (en) 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
EP2891493A4 (en) 2012-08-31 2016-05-18 Astellas Pharma Inc MEDICAL COMPOSITION ADMINISTERED ORALLY
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
DK3024474T3 (da) * 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
EP3220942B1 (en) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) * 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
CN110730658B (zh) 2017-05-31 2023-01-24 思佰益药业股份有限公司 膀胱过度活动的预防剂或治疗剂
CN117695287A (zh) 2017-06-06 2024-03-15 住友制药(苏州)有限公司 使用维贝隆以治疗膀胱过度活动症
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
MX2021003980A (es) 2018-12-05 2021-07-21 Urovant Sciences Gmbh Vibegrón para el tratamiento de los síntomas de la vejiga hiperactiva.
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
JPH08509491A (ja) 1993-04-26 1996-10-08 藤沢薬品工業株式会社 胃腸疾患の治療に有用なエタノールアミン誘導体
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
WO1997015549A1 (en) 1995-10-26 1997-05-01 Tokyo Tanabe Company Limited PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
WO1998007445A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
JP2001513551A (ja) * 1997-08-28 2001-09-04 アフェロン コーポレイション 尿失禁の治療
ATE266639T1 (de) 1997-10-17 2004-05-15 Yamanouchi Pharma Co Ltd Amidderivate oder deren salze
CA2315235C (en) 1997-12-18 2009-07-28 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
DE69919860T2 (de) 1998-04-14 2005-08-25 Kissei Pharmaceutical Co., Ltd., Matsumoto 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
WO2000047771A2 (en) * 1999-02-12 2000-08-17 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
US20080009538A1 (en) * 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence

Also Published As

Publication number Publication date
CY1111399T1 (el) 2015-08-05
LU92218I2 (fr) 2014-01-07
WO2004041276A1 (ja) 2004-05-21
AU2003284700A1 (en) 2004-06-07
MXPA05004925A (es) 2005-08-18
CA2503570A1 (en) 2004-05-21
NZ539577A (en) 2007-06-29
FR13C0032I1 (enExample) 2013-08-09
NL300599I2 (enExample) 2017-01-03
KR100967070B1 (ko) 2010-07-01
NO2015001I1 (no) 2015-01-19
RU2005117367A (ru) 2006-01-20
NO2015001I2 (no) 2015-01-26
RU2321401C2 (ru) 2008-04-10
CN100406011C (zh) 2008-07-30
DK1559427T3 (da) 2011-04-26
CY2013023I1 (el) 2015-10-07
US20090093529A1 (en) 2009-04-09
US8835474B2 (en) 2014-09-16
CN1711085A (zh) 2005-12-21
ES2360353T3 (es) 2011-06-03
BR0316080A (pt) 2005-09-27
AU2003284700B2 (en) 2009-05-28
JP3815496B2 (ja) 2006-08-30
US20110230530A1 (en) 2011-09-22
US20060115540A1 (en) 2006-06-01
PT1559427E (pt) 2011-05-27
DE60336334D1 (de) 2011-04-21
EP1559427A4 (en) 2007-05-30
ATE500827T1 (de) 2011-03-15
EP1559427A1 (en) 2005-08-03
PL376771A1 (pl) 2006-01-09
NO334948B1 (no) 2014-08-04
PL211687B1 (pl) 2012-06-29
USRE44872E1 (en) 2014-04-29
IL168121A (en) 2011-12-29
EP1559427B1 (en) 2011-03-09
US7750029B2 (en) 2010-07-06
CA2503570C (en) 2011-04-19
LU92218I9 (enExample) 2019-01-17
JPWO2004041276A1 (ja) 2006-03-02
NO20052691D0 (no) 2005-06-06
FR13C0032I2 (fr) 2014-03-07
CY2013023I2 (el) 2015-10-07
KR20050072809A (ko) 2005-07-12
ZA200503510B (en) 2006-12-27
SI1559427T1 (sl) 2011-06-30
NO20052691L (no) 2005-07-15
BE2013C040I2 (enExample) 2023-03-07

Similar Documents

Publication Publication Date Title
HUS1300027I1 (hu) Aktív összetevõként ecetsav-anilid származékait tartalmazó orvosság túlmûködõ húgyhólyag kezelésére
NO20044974L (no) Imidazo [1,2-a]pyrazin-8-ylaminer, fremgangsmater for fremstilling og anvendelse derav
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
CA1184501A (en) Antiparkinsonian agent
NO20032510L (no) Organiske forbindelser
EP0638071A1 (en) HETEROCYCLIC CARBONIC ACID DERIVATIVES THAT CAN BIND TO RARE RECEPTORS.
EP0228893A3 (en) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
NO20052817D0 (no) Anvendelse av EDG2-reseptor i en dyremodell for hjertesvikt
DE69430465D1 (de) Hemmung uteriner Fibrose
HRP20041026A2 (en) Polycyclic compounds as potent alpha2-adrenoceptor antagonists
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
EP1669345A4 (en) ESTER DERIVATIVE AND MEDICAL USE THEREOF
DE60230629D1 (de) Verwendung von 2,5-dihydroxybenzolsulfonsäure-derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
CN2417896Y (zh) 用于构成木人桩的围带式活动桩肢
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
WO2002056869A3 (en) Method for treating sexual disorders
WO2002056870A3 (en) Method for treating sleep disorders
ITMI20000376A0 (it) Allomorfo del cloridrato dell'isomero z di derivato di alchilamminofurano procedimento per la sua produzione e composizione farmaceutica che
WO2002056868A3 (en) Method for treating stress or tension
CA2394794A1 (en) Methods for preparing pharmaceutical formulations
WO2005097113A3 (en) 5-ht2b receptor antagonists
NO951865L (no) Quinuclidin-derivat som substans-P antagonist
IT9041520A0 (it) Estere etilico dell'acido 6-bromo-5-idrossi-4-dimetilamminometil-1 -metil-2-feniltiometilindol-3-carbossilico idrocloruro monoidrato, procedimento per il suo ottenimento e farmaco ad azione antivirale, interferoinducente e immunomodulante a base di esso